By Gina Shaw Original Source: FPI-2119 investigational antibiotic A novel antibiotic that targets penicillin-binding proteins (PBPs) without relying on a beta-lactam scaffold demonstrated broad in-vitro activity, bactericidal effects, low resistance selection, and encouraging in-vivo efficacy across a series of preclinical studies presented at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation, in Las Vegas, on Jan. 29, 2026. Across four relat

FPI-2119 offers potential solution to multi-drug-resistant Gram-negative infections Original source: https://www.globenewswire.com/news-release/2026/01/29/3228557/0/en/Fedora-Pharmaceuticals-Highlights-Efficacy-of-Novel-Antibiotic-FPI-2119-against-Antimicrobial-resistant-Gram-negative-Bacteria-at-the-2026-IMARI-Conference.html January 29, 2026 08:12 ET  | Source: Fedora Pharmaceuticals, Inc. EDMONTON, Alberta , Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc., a

January 13, 2026 08:00 ET  | Source: Fedora Pharmaceuticals, Inc. Original Source: https://www.globenewswire.com/news-release/2026/01/13/3217762/0/en/Fedora-Pharmaceuticals-has-Re-emerged-to-Unveil-Novel-Class-of-Antibiotics-at-2026-Interdisciplinary-Meeting-on-Antimicrobial-Resistance-and-Innovation-IMARI.html Edmonton, Alberta, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc., a leader in the development of drugs to treat antibiotic-resistant infections, annou

Originally published on the Canadian Antimicrobial Innovation Coalition (CAIC) website. To mark World Antimicrobial Awareness Week,...